Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

While Eli Lilly ... a new top executive will be able to address the company's challenges. "Although it might satisfy some for investors to drive a CEO transition, without meaningful change in ...

Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc analysis of its completed Phase 2 RESCUE ...

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Since President Donald J. Trump took office a second time on Jan. 20, leaders across the biotechnology and pharmaceutical ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.